BostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2023 Annual Meeting

Workshop Presentation to Highlight the Potential of AI-Driven Molecular Profiling in Tumors

Poster Presentation Unveils Advancements in Genomic Reference Standards for Validating WES Assays

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT. During the event, BostonGene will also deliver a presentation at the AMP Corporate Workshop day and exhibit at booth 1301.

Details of BostonGene’s presence at AMP are below:

Workshop

Title: Unraveling Tumor Profiles Using an HRD-Enabled CGP Assay and Exome Sequencing with AI-Driven Data Analysis

Date and Time: Wednesday, November 15 | 2:00 PM

Location: 255EF, Second Level

Speaker: Katerina Nuzhdina, R&D, Head of Bioinformatics Pipelines Clinical Integration Division, BostonGene

Tumor molecular characterization is key for advancing precision oncology. In collaboration with Agilent, BostonGene will present its method for detecting somatic variants from cancer samples, enabling large-scale data analyses. The approach combines whole exome sequencing based on Agilent SureSelect technology with BostonGene’s AI-driven best-in-class analytics to identify SNVs, indels, CNAs, TMB, MSI, HRD, and translocations.

Poster Presentation

Title: Developing Bespoke Genomic Reference Standards for Validating Somatic Mutation Detection in Clinical Whole Exome Sequencing Assays

Date and Time: Friday, November 17 | 9:15 AM – 10:15 AM

Location: Salt Palace Convention Center

Presenter: Anastasiya Yudina, BostonGene

With the increasing use of whole exome sequencing (WES) in precision oncology on FFPE tumor samples, the establishment of robust validation procedures to ensure accurate and reliable WES assay results is necessary. While germline variant calling reference standards are common, reference standards for somatic variant calling require optimization to be used for WES assay validation at the exome-wide level. To address these challenges, BostonGene developed a method for obtaining reference standards and established optimal thresholds for accurate somatic mutation calling in FFPE samples.

Please visit the AMP 2023 Annual Meeting & Expo website for more information. Abstracts are also published in the online-only supplement to the Journal of Molecular Diagnostics.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231113450571/en/